Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704 · View on ClinicalTrials.gov ↗
Study Summary
This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition affecting central vision (what one sees straight ahead). The purpose of this study is to evaluate the progression rate of Geographic Atrophy in eyes of patients treated with cemdisiran alone or in combination with pozelimab compared to those treated with placebo. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug(s) * How much study drug(s) are in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pozelimab
- DRUG Cemdisiran
Study Locations (20)
California
- Retina Vitreous Associates Medical Group — Beverly Hills
- Retina Specialists of Beverly Hills- Department of Ophthalmology — Beverly Hills
- The Retina Partners — Encino
- Eye Medical Center of Fresno — Fresno
- Retina Consultants of Orange County — Fullerton
- Salehi Retina Institute dba Retina Associates of Southern California — Huntington Beach
- University of California Irvine — Irvine
- University of California San Diego, Jacobs Retina Center — La Jolla
- South Coast Retina Center — Long Beach
- American Institute of Research — Los Angeles
- Kaiser Permanente Los Angeles Medical Center — Los Angeles
- Retinal Consultants Medical Group Inc Modesto — Modesto
- Northern California Retina Vitreous Associates Medical Group, Inc. — Mountain View
Arizona
- Barnet Dulaney Perkins Eye Center-Ophthamalogy — Chandler
- Barnet Dulaney Perkins Eye Center — Phoenix
- Associated Retina Consultants — Phoenix
- Retinal Research Institute — Phoenix
- Retina Macula Institute of Arizona — Scottsdale
- Retina Associates of Tuscan — Tucson
Arkansas
- Retina Partners of Northwest Arkansas, PLLC — Springdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 975 participants |
| Start Date | 2024-10-30 |
| Est. Completion | 2032-05-21 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06541704
The ClinicalTrials.gov registry entry for NCT06541704 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 975 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 290 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Age-related Macular Degeneration (AMD) appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06541704 reports 20 study locations spanning 3 distinct geographic areas — top geographies include California, Arizona, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06541704 about?
NCT06541704 is a clinical study titled "A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy". This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye c...
What is the current status of trial NCT06541704?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 975 participants. The study started on 2024-10-30. Estimated completion is 2032-05-21.
What conditions does trial NCT06541704 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration (AMD), Geographic Atrophy (GA). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06541704?
The interventions under investigation include: Placebo (DRUG), Pozelimab (DRUG), Cemdisiran (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06541704?
This trial is sponsored by Regeneron Pharmaceuticals, which has 290 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06541704 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.